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77 Potential of denufosol as an early intervention in CF lung disease:
efﬁcacy in patients with minimal pharmacotherapy in a US phase 3
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Introduction: Early onset of lung disease in CF necessitates early intervention with
disease-modifying agents. Denufosol, a novel ion channel regulator, stimulates Cl−
transport, inhibits Na+ absorption and increases ciliary beat frequency regardless
of CFTR genotype. The potential of denufosol as an early intervention agent was
explored in patients (pts) on limited background pharmacotherapy.
Methods: Denufosol was studied in pts on 0 to 2 concurrent pharmacotherapies
for CF lung disease from a Phase 3, placebo (PL)-controlled double-blind (DB)
trial (TIGER-1) in pts on US standard of care 5 yrs with FEV175 % pred. The
24-wk DB phase was followed by a 24-wk denufosol-only open label extension
(OLE).
Results: The demographics of PL (n = 34) and denufosol (n = 37) pts with 91% and
93% pred. FEV1 were similar to intent-to-treat population (ITT). In DB phase, the
denufosol treatment resulted in net FEV1 improvement over PL of 5.7% (p = 0.028)
or 100ml (p = 0.059) (% change from baseline [CFB] or CFB). The net improvement
over PL was 6.4 % (p = 0.011) in % pred. FEV1. In OLE, the pts on 48 wks of
denufosol improved in FEV1 by 12% (183ml) and by 4% pred. FEV1. These
treatment effects were greater than observed in ITT where >50% of pts used at
least 4 pharmacotherapies. Denufosol was well tolerated with comparable safety
proﬁle to PL.
Conclusions: Due to its mechanism of action designed to correct the ion transport
defect, denufosol may be an ideal early intervention treatment in CF lung disease.
The clinically meaningful improvement in pts on denufosol who are >90% predicted
and on limited medications highlights the potential of denufosol as a ﬁrst line agent
in CF pts.
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Introduction: Early onset of CF disease in small airways calls for disease-
modifying therapies that treat small airways and possess a favorable safety proﬁle.
Denufosol, an inhaled ion channel regulator, increases Cl− transport, inhibits Na+
absorption and stimulates ciliary beat frequency regardless of CFTR genotype.
This work examines denufosol’s aerosol and PK properties and their impact on its
potential as an early intervention agent.
Methods: Denufosol droplet size generated by PARI LC STAR was measured with
the Next Generation Impactor and laser diffraction. The systemic exposure was
evaluated by measuring denufosol plasma concentrations in a Phase 3, placebo (PL)-
controlled double-blind (DB) trial (TIGER-1) in pts 5 yrs with FEV1  75% pred.
Efﬁcacy was assessed by pulmonary function tests including FEF25−75.
Results: Denufosol’s median droplet size (3.4 to 3.8 mm, 2.4 mmMMAD) is suitable
for reaching small airways. Statistically signiﬁcant improvement in FEF25−75 over
PL in patients <110% pred. FEV1 (p = 0.025) supports the in vitro data suggesting
clinical ability to nebulize denufosol to smaller airways. Following inhalation, there
was little to no systemic exposure to denufosol after the ﬁrst dose, no evidence of
accumulation with chronic TID dosing and a favorable safety proﬁle.
Conclusion: Denufosol is an investigational treatment designed to correct the ion
transport defect in CF lung disease. Denufosol nebulized in LC STAR is suitable
for delivery to the smaller airways as supported by FEF25−75 results. The ability to
treat small airways and the lack of systemic exposure make denufosol a promising
early intervention therapy for CF lung disease.
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Background: Inhaled dry powder Mannitol (DPM) is an osmotic agent that increases
water content of the ASL, improves mucociliary clearance and cough clearance [1]. A 6
month-double blind (DB) phase III trial of DPM (400mg bd), in a broad representative
CF population, demonstrated a sustained clinically meaningful FEV1 improvement
(6.5% from baseline) irrespective of concomitant rhDNase use [2]. This open label
phase (OLP) aimed to further assess safety and efﬁcacy of DPM for 12−18 months.
Methods: 198 patients (112 DPM, 86 control) who completed the DB phase were
given the option of entering the OLP and receiving DPM at 400mg bd. The OLP
followed patients at week 38, 52, 64 and 78 to assess lung function, safety and review
pulmonary exacerbations.
Results: 85.9% of patients who completed the DB phase elected to continue into the
OLP. Preliminary data showed that patients on DPM maintained the increase in FEV1
seen in the DB phase throughout the OLP (Table 1). Control group patients had an
absolute mean FEV1 % predicted improvement of 5.4% (p< 0.05) after switching to
DPM. The ﬁnal 12 month OL patient visit (wk 78) will be March 2010 and additional
data from this OLP will be presented.
Table 1. Preliminary FEV1% predicted OLP results
Group Start of the ﬁrst OLP (week 26) End of the ﬁrst OLP (week 52)
Mannitol–Mannitol 67.6% (SD±16.3) (n = 97) 67.8% (SD±17.3) (n = 82)
Control–Mannitol 61.7% (SD±17.0) (n = 71) 67.8% (SD±25.5) (n = 52)
Conclusions: DPM shows sustained improvement in FEV1. Control subjects who
changed to DPM in the OLP showed a similar improvement in FEV1 as seen for
patients on DPM in the DB phase, further conﬁrming the efﬁcacy and safety of DPM
therapy in patients with CF.
Reference(s)
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Background: There are no new antibiotics in development to address infections caused
by Pseudomonas aeruginosa (PA). PA is an environmental organism that causes chronic
destructive lung infection in patients with CF. Quorum sensing (QS), an intercellular
signalling mechanism coordinating gene expression has a key role in PA’s virulence,
resistance and immune system evasion. Inhibiting QS may reduce the virulence of this
devastating pathogen.
Aim: To determine the in vitro efﬁcacy of a garlic supplement upon the inhibition of
QS in clinical strains of PA.
Methods: A laboratory strain (PA01) and clinical isolates from the sputa of 5
children with CF and chronic pulmonary PA infection were tagged using chromosomal
transcriptional lux-based fusions (CTX::lux) to the QS controlled genes pqsA and lasB.
Isolates were grown in control media or media infused with garlic oil. Growth and
luminescence of the transcriptional fusions were measured. The reduction in expression
was calculated between the difference in expression in garlic and expression in control
media.
Results: See the table.
Strain Mean reduction of QS target gene expression when grown in
garlic-infused media [absolute value; relative luminescence
units ×104 (standard error of mean)]a
lasB pqsA
PA01 8.44 (1.53) 10.57 (1.86)
PA03 1.86 (0.21) 4.06 (0.34)
PA06 4.27 (0.43) 4.06 (0.23)
PA09 8.91 (0.62) 27.53 (2.54)
PA15 5.82 (0.41) 7.48 (0.30)
PA21 0.91 (0.08) 2.10 (0.16)
aExperiment repeated in triplicate − all values signiﬁcant, p< 0.05.
Conclusion: Garlic oil reduces the expression of two genes which represent major loci
of control of QS in all clinical strains tested. This further advances the potential for
translation as a therapeutic candidate.
